Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development [Yahoo! Finance]
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court [Yahoo! Finance]
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND